4-HO-DALT explained

4-HO-DALT, also known as 4-hydroxy-N,N-diallyltryptamine or as daltocin, is a serotonin receptor agonist and serotonergic psychedelic of the tryptamine and 4-hydroxytryptamine families.^{[1] [2] [3]} It has been encountered as a novel designer drug.

Use and effects

4-HO-DALT was not included nor mentioned in Alexander Shulgin's book TiHKAL (Tryptamines I Have Known and Loved).^[4] However, in a subsequently released entry, it was briefly mentioned. He does not appear to have synthesized or tested it and its properties were not described, but Shulgin hypothesized that the drug, in its prodrug form 4-AcO-DALT, would have a very rapid onset of action. Subsequently, 4-HO-DALT has emerged as a novel designer drug.^[5] It is said to produce hallucinogenic effects similar to those of 4-HO-DiPT and 4-HO-DPT.

Pharmacology

Pharmacodynamics

4-HO-DALT binds to many of the serotonin receptors, including the serotonin 5-HT_2A receptor, as well as other targets. The drug acts as a potent full agonist of the serotonin 5-HT_2A and 5-HT_2B receptors, whereas it showed 60-fold lower potency as an agonist of the serotonin 5-HT_2C receptor compared to the serotonin 5-HT_2A receptor. It produces the head-twitch response, a behavioral proxy of psychedelic-like effects, in rodents.

Chemistry

Analogues

Analogues of 4-HO-DALT include diallyltryptamine (DALT), 4-AcO-DALT, 5-MeO-DALT, 4-HO-MALT, psilocin (4-HO-DMT), 4-HO-DET (ethocin), 4-HO-DPT, and 4-HO-DiPT, among others.

History

4-HO-DALT was first described by Alexander Shulgin in a follow-up entry of TiHKAL (Tryptamines I Have Known and Loved) in 2004. Subsequently, it was further described in 2017 and thereafter. The drug was encountered online as a novel designer drug by 2014. In 2023, it was found to be sold as an analytical standard.

Society and culture

Legal status

Canada

4-HO-DALT is not a controlled substance in Canada as of 2025.^[6]

See also

• Substituted tryptamine

External links

• 4-HO-DALT - Isomer Design
• The Small & Handy 4-HO-DALT Thread - Bluelight

Notes and References

1. Klein LM, Cozzi NV, Daley PF, Brandt SD, Halberstadt AL . Receptor binding profiles and behavioral pharmacology of ring-substituted N,N-diallyltryptamine analogs . Neuropharmacology . 142 . 231–239 . November 2018 . 29499272 . 6230509 . 10.1016/j.neuropharm.2018.02.028 .
2. Glatfelter GC, Naeem M, Pham DN, Golen JA, Chadeayne AR, Manke DR, Baumann MH . Receptor Binding Profiles for Tryptamine Psychedelics and Effects of 4-Propionoxy-N,N-dimethyltryptamine in Mice . ACS Pharmacology & Translational Science . 6 . 4 . 567–577 . April 2023 . 37082754 . 10111620 . 10.1021/acsptsci.2c00222 .
3. Brandt SD, Kavanagh PV, Dowling G, Talbot B, Westphal F, Meyer MR, Maurer HH, Halberstadt AL . Analytical characterization of N,N-diallyltryptamine (DALT) and 16 ring-substituted derivatives . Drug Testing and Analysis . 9 . 1 . 115–126 . January 2017 . 27100373 . 5412731 . 10.1002/dta.1974 .
4. https://isomerdesign.com/pihkal/read/tk/56#5530 "Another direction possible for modifying the structure would be to relocate the oxygen in indole ring over to the 4-position. 4-Methoxytryptamine is commercially available, and it should be directly substitutable for the 5-methoxytryptamine used in this synthetic process giving rise to 4-MeO-DALT. Yet further out, what about starting the 4-benzyloxytryptamine and walking the same path? The product could be easily stripped of the benzyl ether by the usual catalytic hydrogenation, giving rise to the diallyl analogue of psilocin, 4-HO-DALT. I would wager a ten dollar bet that the acetate ester of this material, 4-AcO-DALT would be in the brain within minutes of swallowing the pill."
5. Web site: 4-HO-DALT (4-hydroxy DALT) . АИПСИН . ru . 1 January 2026.
6. Web site: Controlled Drugs and Substances Act . Department of Justice Canada . 19 January 2026.